The MINT platform, derived from Sangamo's extensive experience in protein-DNA interactions through its zinc finger technology. Sangamo Therapeutics recently presented critical pre-clinical data on its innovative next-generation integrase technology, the Modular Integrase (MINT) platform, highlighting a significant advancement in the field of genome editing. The announcement came as part of their participation at the 27th Amer...
$サンガモ セラピューティクス(SGMO.US)$Sangamo Therapeutics To Present Neurology-Focused Pre-Clinical Data From Epigenetic Regulation, Capsid Delivery And Genome Engineering Platforms At 27th ASGCT Annual Meeting
The market anticipates continued poor revenue growth, potentially suppressing the P/S ratio. The company's forecast of declining revenue contributes to its low P/S. Without major changes, a drastic stock price increase seems unlikely.
$サンガモ セラピューティクス(SGMO.US)$Sangamo Therapeutics Announces Data From STAC-BBB Demonstrating 'Robust Penetration of the Blood-brain Barrier (BBB) and Strong Transgene Expression Throughout the Central Nervous System (CNS) of NHPs'
Trytosaveabitスレ主Benjamin’s:
It’s been on a pretty decent uptrend for 13 days now! In less than 30 days it’s gone from .39 to today high of 1.09! I’ve been in since just before Christmas! And I’m going to continue to ride for as long as I can! Hehehe. So I’m holding unless it drops below.73! GL
サンガモ セラピューティクスに関するコメント
Sangamo Therapeutics recently presented critical pre-clinical data on its innovative next-generation integrase technology, the Modular Integrase (MINT) platform, highlighting a significant advancement in the field of genome editing. The announcement came as part of their participation at the 27th Amer...
まだコメントはありません